An observational study in Neuralgia and Herpes Zoster, sponsored by Analgesic Solutions. Status unknown at 1 site in United States. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2010-08-05.
Sponsored by Analgesic Solutions · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 291 studies in Neuralgia with a site in United States — 50 open to participants now, 61 under way, 5 of them phase 3. Neuralgia · United States.
Among the 291 studies in Neuralgia with a site in United States, this one is the 23rd largest by planned enrollment of the 28 observational ones that give a count, is one of 7 that started in 2010, is one of 28 observational ones, and was the 62nd registered.
1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.
Browse Neuralgia studies →50 of the 291 studies in Neuralgia with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 50+
Stanford University · Sites in United States
Ages 18+
James J. Peters Veterans Affairs Medical Center · Sites in United States
Ages 22+
EicOsis Human Health Inc. · Sites in United States
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
291 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 94 · Phase 3 26 · Phase 4 14
First in 1993; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 102 across 232 observational studies indexed under Neuralgia.
Median enrollment 40 across the 261 interventional studies, 53 across the 28 observational. Of the 193 that completed or were terminated, 86 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 291 have an industry lead sponsor. The 10 most frequent:
Analgesic Solutions is the lead sponsor of 8 studies on the registry; none are open to participants now.
Analgesic Solutions has 2 studies filed under Neuralgia — fewer than ten, so there is no comparison to draw.
27 of the studies in Neuralgia with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06696443Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | 2027-01-25 |
| NCT07231419Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy | 2027-04-06 |
| NCT06628908Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | 2027-05-31 |
| NCT06848348Dogwood Therapeutics Inc.Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain | 2026-12 |
| NCT04865679Axogen CorporationTolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends | 2026-12 |
Add all 27 to your calendar (.ics) → With an account.
Among the 291 studies in Neuralgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Post herpetic neuralgia (PHN) is an undertreated condition. It is a type of neuropathic pain (NP), or pain caused by abnormal activity of sensory nerves. Its mechanisms are not fully understood, and medication trials for PHN pain and other types of NP are frequently unsuccessful.
There has been extensive investigation aimed at identifying and understanding the specific mechanisms of NP. While some of these tests are inexpensive and easy to perform at the bedside, many require expensive tools and highly equipped laboratory facilities. Further, there is no standard method for assessment of pain in NP patients.
The investigators aim to test a Bedside Sensory Testing Kit (assessment for Neuropathic Pain) on a small number of patients with PHN.
The purpose of the Kit is to identify mechanisms of pain. The goal of this research is to design a way to classify patients with PHN based on what mechanisms are causing their pain, since this may help predict the best medications for individual patients.
We hypothesize: (a) that a Bedside Sensory Testing Kit for PHN can be designed such that it works efficiently with Subjects and Investigators, is tolerated well by Subjects, and is statistically reliable between Investigators; (b) that the sensory testing kit can distinguish between PHN patients with different sensory qualities to their pain which may be caused by different underlying pain mechanisms.
The subjects will be patients with postherpetic neuralgia who voluntarily participate and meet eligibility criteria. The study participants will complete a brief questionnaire and undergo three rounds of the BSTK, performed by two study investigators. The items in the BSTK correspond to a series of sensory assessments, each of which are aimed to contribute to the characterization of individuals' PHN pain.
Community sample patients with postherpetic neuralgia who voluntarily participate and meet eligibility criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Demonstrate usability of the BSTK.
Analysis of subject feedback regarding clarity of instructions, burden of study procedures, and overall experience. Analysis of investigator observations regarding clinical feasibility, investigator burden, and overall experience.
Time frame: Subject Duration in the study is one (1) clinic visit ( approximatley 2-3 hours). We expect 10 weeks of open enrollment. Total study timeline is 4 months(1 month start up, 2 months enrollment, 1 month clean and analysis, 2 weeks final CSR.
The record gives a start of Jul 2010, a primary completion of Oct 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Analgesic Solutions